Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy

Annals of Pharmacotherapy

Volumn 42, Issue 10, 2008, Pages 1481-1485

  Amara, Shilpa ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Glutamine; Peripheral neuropathy

Indexed keywords

GLUTAMINE; OXALIPLATIN; PACLITAXEL;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DYSESTHESIA; GAIT; HUMAN; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROTOXICITY; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REFLEX; REVIEW; SIDE EFFECT; VIBRATION SENSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMINE; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; TAXOIDS; VINCA ALKALOIDS;

EID: 52949143529     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L179     Document Type: Review

References (20)

1. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2007;11:901-13. DOI dx.doi.org/10.1188/07.CJON.901-913
2. National Cancer Institute. Common terminology criteria for adverse events v3.0. ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 2008 Mar 22).
3. Vahdat L, Kyriakos P, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001;7:1192-7.
4. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23:162-73. DOI dx.doi.org/10.1016/j.soncn.2007.05.001
5. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32:305-11. DOI dx.doi.org/ 10.1188/05.ONF.305-311
6. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol 2005;17:271-6. DOI dx.doi.org/10.1016/j.clon.2004.11.014
7. Wang W, Lin J, Lin T, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12:312-9. DOI dx.doi.org/10.1634/theoncologist.12-3-312
8. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.1.2008. Small cell lung cancer. www.nccn.org/professionals/ physician_gls/PDF/sclc.pdf (accessed 2008 Mar 21).
9. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.2.2008. Non-small cell lung cancer. www.nccn.org/professionals/ physician_gls/PDF/nscl.pdf (accessed 2008 Mar 21).
10. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.1.2008. Colon cancer. www.nccn.org/professionals/physician_gls/PDF/ colon.pdf (accessed 2008 Mar 21).
11. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.2.2008. Breast cancer. www.nccn.org/professionals/physician_gls/PDF/ breast.pdf (accessed 2008 Mar 21).
12. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.1.2008. Ovarian cancer. www.nccn.org/professionals/physician_gls/PDF/ ovarian.pdf (accessed 2008 Mar 21).
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.1.2008. Hodgkin disease/lymphoma. www.nccn.org/professionals/ physician_gls/PDF/hodgkins.pdf (accessed 2008 Mar 21).
14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v.2.2008. Non-Hodgkin's lymphomas. www.nccn.org/professionals/ physician_gls/PDF/nhl.pdf (accessed 2008 Mar 21).
15. Savarese D, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29:501-13. DOI dx.doi.org/10.1016/S0305-7372%2803%2900133-6
16. Decker GM. Glutamine: indicated in cancer care? Clin J Oncol Nurs 2002;6:112-5. DOI dx.doi.org/10.1188/02.CJON.112-115
17. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-42. DOI dx.doi.org/10.1016/S0959-8049(99)00149-5
18. Cassidy J, Tabernero J, Twelves C. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91. DOI dx.doi.org/10.1200/JCO.2004.11.069
19. Garlick PJ. Assessment of the safety of glutamine and other amino acids. J Nutr 2001;131(suppl):2556S-61S.
20. eMedTV. Glutamine supplement information. mental-health.emedtv.com/ mental-health/glutamine-supplement-information.html (accessed 2008 May 9).